Reversal of neuromuscular block

British Journal of Anaesthesia

Volumn 103, Issue 1, 2009, Pages 115-129

  Srivastava, A ^a   Hunter, J M ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Neuromuscular block, antagonists; Neuromuscular block, neostigmine

Indexed keywords

AMINOSTEROID; ATRACURIUM; ATROPINE; BENZYLISOQUINOLINIUM; CHOLINESTERASE INHIBITOR; CONTRACEPTIVE AGENT; CORTISONE; CYCLODEXTRIN DERIVATIVE; EDROPHONIUM; FLUCLOXACILLIN; FUSIDIC ACID; GALLAMINE; GAMMA CYCLODEXTRIN; GLYCOPYRRONIUM BROMIDE; NEOSTIGMINE; NEUROMUSCULAR BLOCKING AGENT; PANCURONIUM; PHYSOSTIGMINE; PYRIDOSTIGMINE; QUINOLINE DERIVATIVE; REMIFENTANIL; ROCURONIUM; SEVOFLURANE; STEROID; SUGAMMADEX; TUBOCURARINE CHLORIDE; UNCLASSIFIED DRUG; VECURONIUM; VERAPAMIL; CYCLODEXTRIN; GAMMA CYCLODEXTRIN DERIVATIVE;

BRADYCARDIA; BRONCHOSPASM; CLINICAL TRIAL; DISEASE SEVERITY; DRUG ANTAGONISM; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG STRUCTURE; GENERAL ANESTHESIA; HISTORY OF MEDICINE; HUMAN; INCIDENCE; NAUSEA; NAUSEA AND VOMITING; NEUROMUSCULAR BLOCKING; NONHUMAN; PARALYSIS; POST TETANIC POTENTIATION; POSTOPERATIVE NAUSEA AND VOMITING; POSTOPERATIVE RESIDUAL PARALYSIS; PRIORITY JOURNAL; QT PROLONGATION; REVIEW; SINGLE DRUG DOSE; ANESTHETIC RECOVERY; ANIMAL; DRUG EFFECT; NEUROMUSCULAR SYNAPSE; POSTOPERATIVE COMPLICATION;

ANESTHESIA RECOVERY PERIOD; ANIMALS; CHOLINESTERASE INHIBITORS; CLINICAL TRIALS AS TOPIC; CYCLODEXTRINS; GAMMA-CYCLODEXTRINS; HUMANS; NEUROMUSCULAR BLOCKADE; NEUROMUSCULAR BLOCKING AGENTS; NEUROMUSCULAR JUNCTION; POSTOPERATIVE COMPLICATIONS;

EID: 67650713727     PISSN: 00070912     EISSN: 14716771     Source Type: Journal    
DOI: 10.1093/bja/aep093     Document Type: Review

References (125)

1. Abe K, Takada K, Yoshiya I. Intraoperative torsade de pointes ventricular tachycardia and ventricular fibrillation during sevo-flurane anesthesia. Anesth Analg 1998; 86: 701-2
2. Abrams RE, Horkbein TF. Inability to reverse pancuronium blockade in a patient with renal failure and hepatic disease. Anesthesiology 1975; 42: 362-4
3. Ali HH, Utting JE, Gray TC. Quantitative assessment of residual antidepolarizing block. II. Br J Anaesth 1971; 43: 478-85
4. Amao R, Zornow MH, Cowan MR, Cheng DC, Allard M. Sugammadex safely reverses rocuronium-induced blockade in patients with pulmonary disease. Anesthesiology 2007; 107: A1582
5. Andersen B, Madsen JV, Schurizek BA, Juhl B. Residual curariza-tion: a comparative study of atracurium and pancuronium. Acta Anaesthiol Scand 1988; 32: 79-81
6. Baillard C, Clec'h C, Catineau J, et al. Postoperative residual neuromuscular block: a survey of management. Br J Anaesth 2005; 95: 622-6
7. Baillard C, Gehan G, Reboul-Marty J, Larmignat P, Samama CM, Cupa M. Residual curarization in the recovery room after vecuronium. Br J Anaesth 2000; 84: 394-5
8. Ballance J. Obituary. Professor Thomas Cecil Gray. Anaesthesia 2008; 63: 564-5
9. Barrow MEH, Johnson JK. A study of anticholinesterase and anticurare effects of some cholinesterase inhibitors. Br J Anaesth 1996; 38: 420-31
10. Berg H, Roed J, Viby-Mogensen J, et al. Residual neuromuscular block is a risk factor for postoperative pulmonary complications. A prospective, randomized, and blinded study of postoperative pulmonary complications after atracurium, vecur-onium and pancuronium. Acta Anaesthesiol Scand 1997; 41: 1095-103
11. Berry FR, Benson DJ. Renal impairment and prolonged curariza-tion. Anaesth Int Care 1979; 7: 193
12. Bevan DR, Smith CE, Donati F. Postoperative neuromuscular blockade: a comparison between atracurium, vecuronium, and pancuronium. Anesthesiology 1988; 69: 272-6
13. Bevan JC, Collins L, Fowler C, et al. Early and late reversal of rocuronium and vecuronium with neostigmine in adults and children. Anesth Analg 1999; 89: 333-9
14. Bevan JC, Tousignant C, Stephenson C, et al. Dose responses for neostigmine and edrophonium as antagonists of mivacurium in adults and children. Anesthesiology 1996; 84: 354-61
15. Bissinger U, Schimek F, Lenz G. Postoperative residual paralysis and respiratory status: a comparative study of pancuronium and vecuronium. Physiol Res 2000; 49: 455-62
16. Blobner M, Eriksson L, Scholz J, Hillebrand H, Pompei L. Sugammadex (2.0 mg/kg) significantly faster reverses shallow rocuronium-induced neuromuscular blockade compared with neostigmine (50 μ/kg). Eur J Anaesthesiol 2007; 24: 125
17. Bom A, Cameron K, Clark JK, et al. Chemical chelation as a novel method of NMB reversal: discovery of Org 25969. Eur J Anaesthesiol 2001; 18: 99
18. Bom A, Clark JK, Palin R. New approaches to reversal of neuro-muscular block. Curr Opin Drug Discov Dev2002; 5: 793-800
19. Bom A, Hope F. Neuromuscular block induced by rocuronium and reversed by the encapsulating agent Org 25969 can be re-established using the non-steroidal neuromuscular blockers succinylcholine and cis-atracurium. Eur J Anaesthiol 2005; 22: A457
20. Bourgain JL, Debaene B, Meistelman C, Donati F. Respiratory mechanics in anaesthetized patients after neostigmine-atropine. A comparison between patients with and without chronic obstructive pulmonary disease. Acta Anaesthiol Scand 1993; 37: 365-9
21. Bridion Data Sheet. Available from http://www.medsafe.govt.nz/ Profs/Datasheet/b/bridioninj.htm (accessed March 2009)
22. Broadley KJ. Anticholinesterases. Autonomic Pharmacology. London: Taylor & Francis Ltd, 1996; 406
23. Brull SJ, Ehrenwerth J, Connelly NR, Silverman DG. Assessment of residual curarization using low-current stimulation. Can J Anaesth 1991; 38: 164-8
24. Cameron KS, Fielding L, Mason R, et al. Anionic cyclophanes as potential reversal agents of muscle relaxants by chemical chelation. Bioorg Med Chem Lett 2002; 12: 753-5
25. Cammu G, de Baerdemaeker L, den Blauwen N, de May JC, Struys M, Mortier E. Postoperative residual curarization with cisatracurium and rocuronium infusions. Eur J Anaesthesiol 2002; 19: 129-34
26. Cammu G, De Kam PJ, Demeyer I, et al. Safety and tolerability of single intravenous doses of sugammadex administered simultaneously with rocuronium or vecuronium in healthy volunteers. Br J Anaesth 2008; 100: 373-9
27. Cammu G, De Witte J, De Veylder J, et al. Postoperative residual paralysis in outpatients versus inpatients. Anesth Analg 2006; 102: 426-9
28. Cheng CR, Sessler DI, Apfel CC. Does neostigmine administration produce a clinically important increase in postoperative nausea and vomiting? Anesth Analg 2005; 101: 1349-55
29. Dahl V, Pendeville PE, Hollman MW, Heier T, Blobner M. Reversal of rocuronium-induced neuromuscular blockade by sugammadex in cardiac patients. Anesthesiology 2007; 107: A1581
30. Dale HH. The action of certain esters and ethers of choline and their relation to muscarine. J Pharmacol 1914; 6: 147-90
31. -1) profound neuromuscular block by sugammadex: a multicenter, dose-finding and safety study. Anesthesiology 2007; 107: 239-44
32. de Boer HD, van Egmond J, van de Pol F, et al. Sugammadex, a new reversal agent for neuromuscular block induced by rocuro-nium in the anaesthetized Rhesus monkey. Br J Anaesth 2006; 96: 473-9
33. de Boer HD, van Egmond J, van de Pol F, Bom A, Booij LHDJ. Chemical encapsulation of rocuronium by synthetic cyclodextrin derivatives: reversal of neuromuscular block in anaesthetized Rhesus monkeys. Br J Anaesth 2006; 96: 201-6
34. de Boer HD, van Egmond J, van de Pol F, Bom A, Driessen JJ, Booij LHDJ. Time course of action of sugammadex (Org 25969) on rocuronium-induced block in the Rhesus monkey, using a simple model of equilibration of complex formation. Br J Anaesth 2006; 97: 681-6
35. -11 are not associated with Qt/QTc prolongation. Anesthesiology 2007; 107: A1580
36. Debaene B, Plaud B, Dilly MP, Donati F. Residual paralysis in the PACU after a single intubating dose of nondepolarizing muscle relaxant with an intermediate duration of action. Anesthesiology 2003; 98: 1042-8
37. Decoopman M, Cammu G, Suy K, Heeringa M, De Meyer I, van der Meersch E. Reversal of pancuronium induced block by selective relaxant binding agent sugammadex. Eur J Anaesthesiol 2007; 24: 110-1
38. D'Honneur G, Lofaso F, Drummond GB, et al. Susceptibility to upper airway obstruction during partial neuromuscular block. Anesthesiology 1998; 88: 371-8
39. Duvaldestin P, Saada J, Berger JL, D'Hollander A, Desmonts JM. Pharmacokinetics, pharmacodynamics and dose-response relationships of pancuronium in control and elderly subjects. Anesthesiology 1982; 56: 36-40
40. Eikermann M, Zaremba S, Malhotra A, Jordan AS, Rosow C, Chamberlin NL. Neostigmine but not sugammadex impairs upper airway dilator muscle activity and breathing. Br J Anaesth 2008; 101: 344-9
41. Eleveld DJ, Kuizenga K, Proost JH, Wierda JMKH. A temporary decrease in twitch response during reversal of rocuronium-induced muscle relaxation with a small dose of sugammadex. Anesth Analg 2007; 104: 582-4
42. Epemolu O, Bom A, Hope F, Mason R. Reversal of neuromuscu-lar blockade and simultaneous increase in plasma rocuronium concentration after the intravenous infusion of the novel reversal agent Org 25969. Anesthesiology 2003; 99: 632-7
43. Eriksson LI. Reduced hypoxic chemosensitivity in partially paralyzed man. A new property of muscle relaxants? Acta Anaesth Scand 1996; 40: 520-3
44. Eriksson LI. Evidence-based practice and neuromuscular monitoring: it's time for routine quantitative assessment. Anesthesiology 2003; 98: 1037-9
45. Eriksson LI, Sato M, Severinghaus JW. Effect of vecuronium-induced partial neuromuscular block on hypoxic ventilatory response. Anesthesiology 1993; 78: 693-9
46. Eriksson LI, Sundman E, Olsson R, et al. Functional assessment of the pharynx at rest and during swallowing in partially paralyzed humans: simultaneous videomanometry and mechanomyo-graphy of awake human volunteers. Anesthesiology 1997; 87: 1035-43
47. Fawcett WJ, Dash A, Francis GA, Liban JB, Cashman JN. Recovery from neuromuscular blockade: residual curarization following atracurium or vecuronium by bolus dosing or infusions. Acta Anaesthesiol Scand 1995; 39: 288-93
48. Feldman A, Fauvel N. Recovery from a neuromuscular block. In: Pollard B, ed. Applied Neuromuscular Pharmacology. Oxford: Oxford University Press, 1994; 107-22
49. Feldman SA. An interesting case of recurarization. Br J Anaesth 1959; 31: 461
50. Flockton EA, Mastronardi P, Hunter JM, et al. Reversal of rocuronium-induced neuromuscular block with sugammadex is faster than reversal of cisatracurium-induced block with neostig-mine. Br J Anaesth 2008; 100: 622-30
51. Food and Drugs Authority. Anesthetic and Life Support Drugs Advisory Committee core presentation. 2008; Available from http://www.fda.gov/ohrms/ dockets/ac/08/slides/ 2008-4346s1-01-Schering-Plough-corebackup.pdf March 11 (accessed March 2009)
52. Fridericia LS. The duration of systole in an electrocardiogram in normal humans and in patients with heart disease. Ann Noninvasive Electrocardiol 2003; 8: 343-51
53. Gijsenbergh F, Ramael S, Houwing N, van Iersel T. First human exposure of Org 25969, a novel agent to reverse the action of rocuronium bromide. Anesthesiology 2005; 103: 695-703
54. Gottlieb JB, Sweet RB. The antagonism of curare: the cardiac effects of atropine and neostigmine. Can Anaesth Soc J 1963; 10: 114-21
55. Gray TC. D-Tubocurarine chloride. Proc R Soc Med 1948; 41: 559-68
56. Gray TC, Halton J. A milestone in anaesthesia? Proc R Soc Med 1946; 39: 400-8
57. Griffith HR, Johnson GE. The use of curare in general anesthesia. Anesthesiology 1942; 3: 418-2
58. Groudine SB, Soto R, Lien C, Drover D, Robert K. A randomized, dose-finding, phase II study of the selective relaxant binding drug, Sugammadex, capable of safely reversing profound rocuronium-induced neuromuscular block. Anesth Analg 2007; 104: 55-62
59. Grove SJ, Kaur J, Muir AW, et al. Oxyaniliniums as acetylcholin-esterase inhibitors for the reversal of neuromuscular block. Bioorg Med Chem Lett 2002; 12: 193-6
60. Hammond J, Wright D, Sale J. Pattern of change of bronchomo-tor tone following reversal of neuromuscular blockade. Br J Anaesth 1983; 55: 955-9
61. Havill JH, Mee AD, Wallace MR, Chin LS, Rothwell RP. Prolonged curarization in the presence of renal impairment. Anaesth Int Care 1978; 6: 234-8
62. Hayes AH, Mirakhur RK, Breslin DS, Reid JE, McCourt KC. Postoperative residual block after intermediate-acting neuromuscular blocking drugs. Anaesthesia 2001; 56: 312-8
63. Henning RH, Nelemans A, Houwertjes M, Agoston S. Reversal by suramin of neuromuscular block produced by pancuronium in the anaesthetized rat. Br J Pharmacol 1993; 108: 717-20
64. Hope F, Bom A. Org 25969 reverses rocuronium-induced neu-romuscular blockade in the cat without important haemodynamic effects. Eur J Anaesthesiol 2001; 18: 99
65. Hovorka J, Korttila K, Nelskylä K, et al. Reversal of neuromuscular blockade with neostigmine has no effect on the incidence or severity of postoperative nausea and vomiting. Anesth Analg 1997; 85: 1359-61
66. Hunter JM, Flockton EA. The doughnut and the hole: a new pharmacological concept for anaesthetists. Br J Anaesth 2006; 97: 123-6
67. Husain MA, Roberts JB, Thomas BH, Wilson A. Metabolism and excretion of 3-hydroxyphenyltrimethylammonium and neostig-mine. Br J Pharmacol 1969; 35: 344-50
68. ICH Guidance for Industry. E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for U.S. Department of Health and Human Services Food and Drug Administration. 2005; Available from http://www.fda.gov/cber/ guidelines.htm (accessed February 2009)
69. Jenkins IR. Three cases of apparent recurarization. Br J Anaesth 1961; 33: 314
70. Jones JE, Hunter JM, Utting JE. Use of neostigmine in the antagonism of residual neuromuscular blockade produced by vecuronium. Br J Anaesth 1987; 59: 1454-8
71. Jones RK, Caldwell JE, Brull SJ, Soto RG. Reversal of profound rocuronium-induced blockade with sugammadex: a randomized comparison with neostigmine. Anesthesiology 2008; 109: 816-24
72. Joshi GP, Garg SA, Hailey A, Yu SY. The effects of antagonizing residual neuromuscular blockade by neostigmine and glycopyr-rolate on nausea and vomiting after ambulatory surgery. Anesth Analg 1999; 89: 628-31
73. King MJ, Milazkiewicz R, Carli F, Deacock AR. Influence of neo-stigmine on postoperative vomiting. Br J Anaesth 1988; 61: 403-6
74. Kirkegaard-Nielsen H, Helbo-Hansen HS, Lindholm P, Severinsen IK, Pedersen HS, Jensen EW. Optimum time for neostigmine reversal of atracurium-induced neuromuscular blockade. Can J Anaesth 1996; 43: 932-8
75. Kirkegaard-Nielsen H, Helbo-Hansen HS, Lindholm P, Severinsen IK, Bülow K. Time to peak effect of neostigmine at antagonism of atracurium-, or vecuronium-induced neuromus-cular block. J Clin Anesth 1995; 7: 635-9
76. Kleinsasser A, Kuenszberg E, Loeckinger A, et al. Sevoflurane, but not propofol, significantly prolongs the QT interval. Anesth Analg 2000; 90: 25-7
77. Kopman AF, Kopman DJ, Ng J, Zank LM. Antagonism of profound cisatracurium and rocuronium block: the role of objective assessment of neuromuscular function. J Clin Anesth 2005; 17: 30-5
78. Kopman AF, Zank LM, Ng J, Neuman GG. Antagonism of cis-atracurium and rocuronium block at a tactile train-of-four count of 2: should quantitative assessment of neuromuscular function be mandatory? Anesth Analg 2004; 98: 102-6
79. Kovac AL. Prevention and treatment of postoperative nausea and vomiting. Drugs 2000; 59: 213-43
80. Läwen A. Über die Verbindung Lokalanaesthesie mit der Narkose, über hohe Extradural Anaesthesie und epidurale Injektionen anaesthesierende Loesungen bei tabetischen Magenkriesen. Beit Klin Chir 1912; 80: 168-9
81. Lee C, Jahr JS, Candiotti K, Warriner B, Zornow MH. Reversal of profound rocuronium NMB with sugammadex is faster than recovery from succinylcholine. Anesthesiology 2007; 107: A988
82. Lee MR. Curare: the South American arrow poison. J R Coll Physicians Edinb 2005; 35: 83-92
83. Lemmens HJM, El-Orbany MI, Berry J, Martin G. Sugammadex reverses profound vecuronium blockade more rapidly than neostigmine. Anesthesiology 2007; 107: A1578
84. Lennmarken C, Lofstrom JB. Partial curarization in the postoperative period. Acta Anaesthesiol Scand 1984; 28: 260-2
85. -1 with glycopyrrolate increases postoperative nausea in women after laparoscopic gynaecological surgery. Acta Anaesthesiol Scand 2001; 45: 495-500
86. Martinez A, Fernandez E, Castro A, et al. N-Benzylpiperidine derivatives of 1,2,4-thiadiazolidinone as new acetylcholinesterase inhibitors. Eur J Med Chem 2000; 35: 913-22
87. Mason R, Bom A. Org 25969 causes selective reversal of neuro-muscular block induced by steroidal NMBs in anaesthetized guinea pigs. Eur J Anaesthesiol 2001; 18: 100
88. McCaul C, Tobin É, Boylan JF, McShane AJ. Atracurium is associated with postoperative residual curarization. Br J Anaesth 2002; 89: 766-9
89. McDonagh DL, Benedict PE, Kovac AL, Drover D, Brister NW. Efficacy and safety of sugammadex for reversal of rocuroniuminduced blockade in elderly patients. Anesthesiology 2007; 107: A1583
90. McEwin L, Merrick PM, Bevan DR. Residual neuromuscular blockade after cardiac surgery: pancuronium vs rocuronium. Can J Anaesth 1997; 44: 891-5
91. Miller RD, Bom A. Org 25969 causes selective reversal of neu-romuscular blockade induced by steroidal NMB's in mouse hemidiaphragm preparation. Eur J Anaesthesiol 2001; 18: 100
92. Miller RD, Van Nyhuis LS, Eger EI, II, Vitez TS, Way WI. Comparative times to peak effect and duration of action of neostigmine and pyridostigmine. Anesthesiology 1974; 41: 27-33
93. -1). Br J Anaesth 2007; 98: 624-7
94. Naguib M, Kopman AF, Ensor JE. Neuromuscular monitoring and postoperative residual curarisation: a meta-analysis. Br J Anaesth 2007; 98: 302-16
95. Nelskylä K, Yli-Hankala A, Soikkeli A, Korttila K. Neostigmine with glycopyrrolate does not increase the incidence or severity of postoperative nausea and vomiting in outpatients undergoing gynaecological laparoscopy. Br J Anaesth 1998; 81: 757-60
96. Pal J. Physostigmin ein Gegengift des Curare. Zentralbl Physiol 1900; 14: 255-8
97. Palin R, Clark JK, Cowley P, et al. Novel piperidinium and pyridi-nium agents as water-soluble acetylcholinesterase inhibitors for the reversal of neuromuscular blockade. Bioorg Med Chem Lett 2002; 12: 2569-72
98. Pedersen T, Viby-Mogensen J, Ringsted C. Anaesthetic practice and postoperative pulmonary complications. Acta Anaesthesiol Scand 1992; 36: 812-8
99. Plaud B, Meretoja O, Pohl B, Mirakhur RK, Raft J. Reversal of rocuronium-induced neuromuscular blockade with sugammadex in paediatric and adult patients. Eur J Anaesthesiol 2007; 24: 124
100. Pleym H, Bathen J, Spigset O, Gisvold SE. Ventricular fibrillation related to reversal of the neuromuscular blockade in a patient with long QT syndrome. Acta Anaesthesiol Scand 1999; 43: 352-5
101. Pratt CI. Bronchospasm after neostigmine. Anaesthesia 1988; 43: 248
102. Pühringer FK, Rex C, Sielenkämper AW, et al. Reversal of profound, high-dose rocuronium-induced neuromuscular blockade by sugammadex at two different time points: an international, multicenter, randomized, dose-finding, safety assessor-blinded, phase II trial. Anesthesiology 2008; 109: 188-97
103. Radulovic M, Spungen AM, Wecht JM, et al. Effects of neostig-mine and glycopyrrolate on pulmonary resistance in spinal cord injury. J Rehabil Res Dev 2004; 4: 53-8
104. Riordan DD, Gilbertson AA. Prolonged curarization in a patient with renal failure. Br J Anaesth 1971; 43: 506-8
105. Rupp SM, Castagnoli KP, Fischer DM, Miller RD. Pancuronium and vecuronium pharmacokinetics and pharmacodynamics in younger and elderly patients. Anesthesiology 1987; 67: 47-9
106. Shibata O, Kanairo M, Zhang S, et al. Anticholinesterase drugs stimulate phosphatidylinositol response in rat tracheal slices. Anesth Analg 1996; 82: 1211-4
107. Shields JA. Heart block and prolonged Q-Tc interval following muscle relaxant reversal: a case report. AANA J 2008; 76: 41-5
108. Shields M, Giovannelli M, Mirakhur RK, Moppett I, Adams J, Hermens Y. Org 25969 (sugammadex), a selective relaxant binding agent for antagonism of prolonged rocuronium-induced neuromuscular block. Br J Anaesth 2006; 96: 36-43
109. Sorgenfrei IF, Norrild K, Larsen PB, et al. Reversal of rocuronium-induced neuromuscular block by the selective relaxant binding agent sugammadex: a dose-finding and safety study. Anesthesiology 2006; 104: 667-74
110. Staals LM, Snoeck MMJ, Driessen JJ, Flockton EA, Heeringa M, Hunter JM. Multicentre, parallel-group, comparative trial evaluating the efficacy and safety of sugammadex in patients with end-stage renal failure or normal renal function. Br J Anaesth 2008; 101: 492-7
111. Suy K, Morias K, Cammu G, et al. Effective reversal of moderate rocuronium- or vecuronium-induced neuromuscular block with sugammadex, a selective relaxant binding agent. Anesthesiology 2007; 106: 283-8
112. Suzuki T, Masaki G, Ogawa S. Neostigmine-induced reversal of vecuronium in normal weight, overweight and obese female patients. Br J Anaesth 2006; 97: 160-3
113. Szejtli J. Past, present, and future of cyclodextrin research. Pure Appl Chem 2004; 76: 1825-45
114. Szente J, Szejtli J. Highly soluble cyclodextrin derivatives: chemistry, properties, and trends in development. Adv Drug Deliv Rev 1999; 36: 17-28
115. Tramèr MR, Fuchs-Buder T. Omitting antagonism of neuromus-cular block: effect on postoperative nausea and vomiting and risk of residual paralysis: a systematic review. Br J Anaesth 1999; 82: 379-86
116. van Egmond J, van de Pol F, Booij L, Bom A. Neuromuscular blockade induced by steroidal NMBs can be rapidly reversed by Org 25969 in anaesthetized monkey. Eur J Anaesthiol 2001; 18: 100
117. van Oldenbeek C, Knowles P, Harper NJ. Residual neuromuscular block caused by pancuronium after cardiac surgery. Br J Anaesth 1999; 83: 338-9
118. Vanlinthout LEH, Booij LHDJ, van Egmond J, Robertson EN. Effects of isoflurane and sevoflurane on the magnitude and time course of neuromuscular block produced by vecuronium, pan-curonium and atracurium. Br J Anaesth 1996; 76: 389-95
119. Viby-Mogensen J, Jorgensen BC, Ording H. Residual curarization in the recovery room. Anesthesiology 1979; 50: 539-41
120. Watcha MF, White PF. Postoperative nausea and vomiting. Its etiology, treatment, and prevention. Anesthesiology 1992; 77: 162-84
121. Welliver M. Update for nurse anesthetists. Part 3. Cyclodextrin introduction to anesthesia practice: form, function, and application. AANA J 2007; 75: 289-96
122. Welliver M, McDonough J, Kalynych N, Redfer R. Discovery, development, and clinical applications of sugammadex sodium, a selective relaxant binding agent. Drugs Design Dev Therapy 2008; 2: 49-59
123. Williams NE, Calvey TN, Chan K. Clearance of neostigmine from circulation during the antagonism of neuromuscular block. Br J Anaesth 1978; 50: 1065-7
124. Wolbrette DL. Drugs that cause Torsades de pointes and increase the risk of sudden cardiac death. Curr Cardiol Rep 2004; 6: 379-8
125. Zhang MQ. Drug-specific cyclodextrins: the future of rapid neuromuscular block reversal? Drugs Future 2003; 28: 347-54